Earnings ·
Enveric Biosciences reported a net loss of $3.0 million for the second quarter ended June 30, 2026, with a basic and…
ENVBEnveric Biosciences, Inc.
Enveric Biosciences reported a net loss of $3.0 million for the second quarter ended June 30, 2026, with a basic and diluted loss per share of $0.76, compared to a net loss of $2.5 million in the prior year period. The company raised approximately $5.0 million through an at-the-market private placement and an additional $1.5 million from warrant exercises, bringing cash-on-hand to $8.3 million as of June 30, 2026. Development highlights include advancing IND-enabling studies for its lead candidate EB-003, reporting non-hallucinogenic profile data in preclinical assays, and securing U.S. patents for its EVM301 Series while receiving a Notice of Allowance for the EVM401 Series. Enveric Biosciences is a biotechnology company focused on developing next-generation neuroplastogenic small molecules to treat psychiatric and neurological disorders.